Clinical Results That Matter
MindVoyage delivers measurable impact on cognitive and emotional health while reducing the burden of care.
Clinical Research
The effectiveness of MindVoyage digital cognitive therapy was demonstrated through a randomized controlled trial.
We have completed the clinical trial of MindVoyage digital cognitive therapy. The study used a randomized assignment design, with the treatment group undergoing an 8-week digital therapy intervention, 2-3 times per week.
Trial Design
After the principal investigator evaluates the matters related to the outpatient trial and explains them to the subjects to obtain consent, clinical trial personnel will arrange to conduct multiple assessments of cognitive function and executive function impairment. The researchers will guide the subjects in using MindVoyage.
Test Duration
20
weeks
Assessment and Tracking
week 0
week 8
week 16
Baseline Assessment
Post-Test Assessment
Follow-Up Assessment
All participants will undergo cognitive therapy assessments at Week 0 (Baseline), Week 8 (Post-Test), and Week 16 (Follow-Up).
Participants were randomly assigned into two groups.
The intervention group received exercise and nutrition education at Week 0, followed by an 8-week digital therapy intervention (2–3 sessions per week).
The control group received only exercise and nutrition education at Week 0.
Research results
After 24 sessions (approximately eight weeks) of using MindVoyage, clinical evaluations showed:
Validation of Assessment Tool
The built-in Brainmate Score shows a high positive correlation with the clinically common MMSE dementia assessment scale (r = 0.70), indicating that MindVoyage's digital cognitive assessment results are highly correlated with traditional clinical assessment scales. This suggests it can serve as an effective auxiliary tool for clinical diagnosis.
Regression Line (r=0.7014934)
Brainmate Score vs MMSE
Correlation between Brainmate Score and MMSE Dementia Assessment Scale
Cost-effectiveness and Care Impact
Economic Benefits
save
93
%
compared to traditional dementia medications
MindVoyage
NT$
51,000
/ year
Dementia Medications
NT$
800,000
/ year
save
98
%
compared to dementia village care
MindVoyage
NT$
51,000
/ year
Dementia Medications
NT$
800,000
/ year
Service Benefits
83
%
Reduction in labor costs
Originally, cognitive therapy and assessment were conducted in a one-on-one format. With MindVoyage, it can be transformed into a one-to-many model, allowing multiple users to interact simultaneously. Labor cost per participant is reduced by approximately 83%, effectively improving service capacity.
30
%
Increase in patient engagement and participation
MindVoyage also significantly boosts patient engagement. Overall participation increased by approximately 30%, which helps promote long-term and consistent care.
International Patents & Academic Publications
Brainmate’s cognitive system is protected by patents across multiple countries and has been published in peer-reviewed international journals — demonstrating both its technological innovation and clinical value.
Patents
Granted Patents
Taiwan I643155
Cognitive Training System
Taiwan I684160
Analysis Prompt System and Method
China CN108335747B
Analysis Prompt System and Method
China CN109326348B
Analysis Prompt System and Method
Taiwan I881461
Method, Computing Device, and Non-Transitory Computer-Readable Medium for Providing Cognitive Training
Patent Application in Progress
Taiwan I643155
Cognitive Training System
Taiwan I684160
Analysis Prompt System and Method
China CN108335747B
Analysis Prompt System and Method
China CN109326348B
Analysis Prompt System and Method
Taiwan I881461
Method, Computing Device, and Non-Transitory Computer-Readable Medium for Providing Cognitive Training
See MindVoyage
in Action
Experience how AI can support therapy and bring peace of mind